Merck & Co., Inc.
Merck & Co., Inc. (MRK): 190 pipeline candidates · 49 upcoming catalysts · ~3 mo cash runway · 179 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
2.8 months
N/A
Lead: Approved
190 candidates
49 upcoming, next in ~32d
0 buys · 16 sells (180d)
A transparent, data-derived signal for Merck & Co., Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$284.3B
Cash
$5.4B
Quarterly Burn
$15.3B
Runway
2.8 mo
Revenue
$16.3B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (190 candidates)
| Drug | Phase |
|---|---|
| 2 NRTIs | Phase 2 |
| Abiraterone | Phase 3 |
| Abiraterone acetate | Phase 3 |
| Acalabrutinib | Phase 3 |
| Acetaminophen | Phase 3 |
| Adempas | Approved |
| Amrubicin | Phase 3 |
| Anagrelide | Phase 3 |
| ART | Phase 3 |
| ATG-022 | Phase 1 |
Showing 10 of 190 candidates. Sign up for full pipeline.
Upcoming Catalysts (49)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3,763
Total value held
$241.59B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 321,975,248 | $38.73B |
| blackrock, inc. | 225,926,330 | $27.18B |
| state street corp | 119,325,673 | $14.45B |
| wellington management group llp | 84,314,971 | $10.14B |
| vanguard portfolio management llc | 67,304,305 | $8.10B |
| geode capital management, llc | 59,558,154 | $7.14B |
| charles schwab investment management inc | 49,765,225 | $5.99B |
| morgan stanley | 47,632,487 | $5.73B |
| fmr llc | 44,516,010 | $5.35B |
| bank of america corp /de/ | 30,774,221 | $3.70B |
Showing top 10 of 3,763 institutional holders of Merck & Co., Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Merck & Co., Inc.'s pipeline?
Merck & Co., Inc. (MRK) has 190 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Merck & Co., Inc.'s lead drug candidate?
Merck & Co., Inc.'s most advanced tracked candidate is 2 NRTIs (Phase 2) for Human Immunodeficiency Virus (HIV) Infection.
What is Merck & Co., Inc.'s next catalyst?
Merck & Co., Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 2, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety, Tolerabilit" — expected July 20, 2026.
What is Merck & Co., Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Merck & Co., Inc. has approximately 2.8 months of cash runway.
What is Merck & Co., Inc.'s market capitalization?
Merck & Co., Inc.'s market capitalization is approximately $284.3B.
Get the full picture on Merck & Co., Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.